Pediatrics

Two doses of BNT162b2 moderately effective for 5- to 11-year-olds

For children aged 5 to 11 years, two doses of BNT162b2 provide moderate protection against documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and symptomatic COVID-19, according to a study published ...

page 9 from 34